GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » ROA %

Wuhan YZY Biopharma Co (HKSE:02496) ROA % : -62.77% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Wuhan YZY Biopharma Co's annualized Net Income for the quarter that ended in Dec. 2023 was HK$-209.68 Mil. Wuhan YZY Biopharma Co's average Total Assets over the quarter that ended in Dec. 2023 was HK$334.05 Mil. Therefore, Wuhan YZY Biopharma Co's annualized ROA % for the quarter that ended in Dec. 2023 was -62.77%.

The historical rank and industry rank for Wuhan YZY Biopharma Co's ROA % or its related term are showing as below:

HKSE:02496' s ROA % Range Over the Past 10 Years
Min: -74.2   Med: -72.32   Max: -62.77
Current: -62.77

During the past 3 years, Wuhan YZY Biopharma Co's highest ROA % was -62.77%. The lowest was -74.20%. And the median was -72.32%.

HKSE:02496's ROA % is ranked worse than
69.23% of 1550 companies
in the Biotechnology industry
Industry Median: -34.97 vs HKSE:02496: -62.77

Wuhan YZY Biopharma Co ROA % Historical Data

The historical data trend for Wuhan YZY Biopharma Co's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co ROA % Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23
ROA %
-74.20 -72.32 -62.77

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Dec23
ROA % -74.20 -72.32 -62.77

Competitive Comparison of Wuhan YZY Biopharma Co's ROA %

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan YZY Biopharma Co's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's ROA % distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's ROA % falls into.



Wuhan YZY Biopharma Co ROA % Calculation

Wuhan YZY Biopharma Co's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-209.68/( (338.188+329.91)/ 2 )
=-209.68/334.049
=-62.77 %

Wuhan YZY Biopharma Co's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Dec. 2023 ))/ count )
=-209.68/( (338.188+329.91)/ 2 )
=-209.68/334.049
=-62.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is one times the annual (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Wuhan YZY Biopharma Co  (HKSE:02496) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-209.68/334.049
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-209.68 / 0)*(0 / 334.049)
=Net Margin %*Asset Turnover
=N/A %*0
=-62.77 %

Note: The Net Income data used here is one times the annual (Dec. 2023) net income data. The Revenue data used here is one times the annual (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Wuhan YZY Biopharma Co ROA % Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan YZY Biopharma Co (HKSE:02496) Business Description

Traded in Other Exchanges
N/A
Address
No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing new class of innovative medicines in respect to anti-tumor bispecific antibody.
Executives
Dragon Merit Holdings Limited 2201 Interest of corporation controlled by you
Robust Sun Holdings Limited 2201 Interest of corporation controlled by you
Cspc Pharmaceutical Group Limited 2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si 2101 Beneficial owner
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Hong Wei
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng
Tong De Qian Yuan Bei Jing Tou Zi Guan Li You Xian Gong Si
Wang Hongjie 2201 Interest of corporation controlled by you
Wu Shangzhi 2201 Interest of corporation controlled by you

Wuhan YZY Biopharma Co (HKSE:02496) Headlines

No Headlines